Objective-In familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD), deposition of abnormal lipoproteins in the renal stroma ultimately leads to renal failure. However, fish-eye disease (FED) does not lead to renal damage although the causative mutations for both FLD and FED lie within the same LCAT gene. This study was performed to identify the lipoproteins important for the development of renal failure in genetically diagnosed FLD in comparison with FED, using high-performance liquid chromatography with a gel filtration column. Approach and Results-Lipoprotein profiles of 9 patients with LCAT deficiency were examined. Four lipoprotein fractions specific to both FLD and FED were identified: (1) large lipoproteins (>80 nm), (2) lipoproteins corresponding to large lowdensity lipoprotein (LDL), (3) lipoproteins corresponding to small LDL to large high-density lipoprotein, and (4) to small high-density lipoprotein. Contents of cholesteryl ester and triglyceride of the large LDL in FLD (below detection limit and 45.8±3.8%) and FED (20.7±6.4% and 28.0±6.5%) were significantly different, respectively. On in vitro incubation with recombinant LCAT, content of cholesteryl ester in the large LDL in FLD, but not in FED, was significantly increased (to 4.2±1.4%), whereas dysfunctional high-density lipoprotein was diminished in both FLD and FED. Conclusions-Our novel analytic approach using high-performance liquid chromatography with a gel filtration column identified large LDL and high-density lipoprotein with a composition specific to FLD, but not to FED. 
L ecithin:cholesterol acyltransferase (LCAT)-deficiency syndromes are rare autosomal recessive diseases, characterized by hypo-α-lipoproteinemia and corneal opacity. 1, 2 They are caused by mutations in the LCAT gene, of which 88 have been reported to date. 3 Severe mutations lead to familial LCAT deficiency (FLD), mild mutations lead to fish-eye disease (FED). In FLD, the mutant LCAT enzyme is either absent in plasma (not secreted from the hepatocyte or rapidly degraded on secretion) or exhibits no catalytic activity on any lipoprotein; in FED, LCAT cannot esterify cholesterol on high-density lipoprotein (HDL; loss of α-activity) but retains its activity on lipoproteins containing apolipoprotein B (β-activity). 1, 2 Likely, the molecular difference is causal to the major clinical difference between FLD and FED: patients with FLD develop renal failure, whereas patients with FED do not. 2, 4 To prevent renal failure in patients with FLD, replacement therapy with recombinant enzyme is currently being developed. [5] [6] [7] [8] Alternatively, we are developing a long-lasting gene therapy by transplantation of human LCAT genetransduced autologous adipocytes. 7, 9 Recombinant LCAT (rLCAT) secreted by the LCAT gene-transduced adipocytes corrected abnormal HDL subpopulations in sera of FED patients in vitro. 10 LCAT catalyzes the esterification of cholesterol with acyl groups hydrolyzed from phospholipids, predominantly on HDL particles. This leads to mature lipoproteins with cores filled with cholesterol ester. LCAT dysfunction leads to decreased maturation of the HDL particle and to increased levels of both its substrates: unesterified cholesterol and phosphatidylcholine. In the absence of LCAT activity, abnormal lipid particles have been observed throughout lipoprotein fractions. [11] [12] [13] [14] The HDL fraction contains disk-shaped particles in rouleaux and small spherical particles. Densitygradient ultracentrifugation followed by electron microscopy revealed that the low-density lipoprotein (LDL) fraction contains 3 abnormal particles with different sizes, lipid composition, and associated apolipoproteins, 11, 12 which were proposed to be important in the pathogenesis of renal manifestation in patients with FLD. [15] [16] [17] [18] Of these, lipoprotein-X (LpX) 19, 20 have been postulated to accumulate in glomeruli, potentially causing the renal damage observed in patients with FLD. [16] [17] [18] In 1 patient with FLD, lipid-lowering therapy led to a reduction of LpX and a concomitant reduction in proteinuria. 21 LpX is phospholipid (PL)-rich and free cholesterol (FC)-rich but triglyceride (TG)-poor particle without apolipoproteins, ranging in size between very low density lipoprotein and large LDL. 22 To characterize the abnormal lipoproteins associated with the renal pathology of FLD, we characterized lipoprotein fractions by analyzing patients with different mutations and manifestations in comparison with another LCAT-deficiency syndrome, FED. We applied high-performance liquid chromatography with a gel filtration column (HPLC-GFC) for the first time to characterize the above abnormal lipoproteins and in fact identified lipoprotein subfractions specific to FLD. The lipid contents and particle size were biochemically determined, and the responsiveness of the lipoproteins against incubation with rLCAT was investigated in vitro.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Lipoprotein Subfractions Specific to LCAT-Deficiency Syndromes
Five patients with FLD (1-5) and 4 patients with FED (6-9) were compared with 4 nonaffected normolipidemic controls. Clinical and molecular characteristics and lipid profiles of the patients are given in Tables 1 and 2 , respectively. Ultracentrifugation fractionation followed by determination of lipid contents was performed in patients 1, 2, and 5 (Table I in the online-only Data Supplement). LCAT α-activities in the patients' sera were all <2% of reference. As expected in LCAT deficiency, mature HDL particles found at fraction (Fr.) 16 and 17 of unaffected controls were absent in the 9 patients (Figure 1 
Abnormal Lipoproteins Are Present in FLD Regardless of Degree of Proteinuria
To study the relationship between lipoproteins and the degree of proteinuria in patients with FLD, lipoproteins between 2 sibling patients with FLD homozygous for the C337Y mutation in LCAT were compared ( Figure 1 , patients 1 and 3). Patient 1 had proteinuria in the nephrotic range (6 g/24 h), whereas patient 3 had only mild proteinuria (0.45 g/L). Next, lipoprotein profiles of a patient with FLD with homozygous for the C98Y 24 mutation before and after a fatrestricted diet, which led to a reduction of proteinuria from 2.0 g/gCr to 0.6 g/gCr, were compared ( Figure 1 , patient 2). All 4 lipoproteins remained present after the diet although Lp1 and Lp8 were decreased to some extent ( Figure 2B ). 
Lp8 and Lp12 to 16 Are Specific to FLD and Not to FED
Lp8 Is a Large LDL, Rich in FC, PL, and TG, and Different From LpX
In comparison with unaffected controls and to patients with FED, CE in the LDL fractions of FLD sera was significantly decreased, whereas TG was increased ( Figure 3A ). In patients with both FLD and FED, FC, TG, and PL in Fr. 8 were significantly higher than in Fr. 9, whereas in controls, FC, TG, and PL in Fr. 8 were significantly lower than in Fr. 9 ( Figure 3B) . As a result, average sizes of Lp8 (Fr. 7-10) in FLD were significantly increased when compared with normal, whereas averaged particle size in FLD was lower than those in FED because of the severe deficiency of CE ( Figure 3C ). The composition of Lp8 in our patients with FLD is consistent with the previously reported FLD-LDL, and not consistent with the lipid characteristics of LpX.
Abnormal Lipid Compositions of FLDSpecific Lps Are Ameliorated by In Vitro Incubation With rLCAT
In vitro rLCAT incubation was performed followed by HPLC-GFC analyses ( Figure III Values for LDL-C were calculated according to Friedewald et al. 29 CE/TC indicates cholesteryl ester/total cholesterol ratio; HDL-C, high-density lipoproteincholesterol; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; and TG, triglyceride. the online-only Data Supplement), indicating LCAT-mediated maturation of HDL. CE and PL contents of Lp8 were significantly increased and decreased, respectively, in FLD after incubation with rLCAT, whereas TG content was not significantly altered ( Figure 4A and 4B) . In FED, composition of Lp8 was not significantly altered by the treatment (Figure 4A and 4B). On incubation with rLCAT, Lp8 increased in size in FLD and it decreased in size in FED ( Figure 4C ). However, FC and PL in Lp12 to 16 decreased on incubation ( Figure 4D ).
Discussion
In this study, 4 lipoprotein fractions specific to LCAT-deficiency syndromes were identified by the HPLC-GFC analysis of samples from genetically diagnosed patients with different mutations and manifestations. Two of these had lipid compositions that were specific to FLD and thus may be involved in causing the renal damage that characterizes FLD. In vitro incubation with rLCAT corrected the abnormal fractions.
Lp1, one of the abnormal lipoproteins characteristic to LCAT-deficiency syndrome, was rich in TG and PL, and associated with the degree of proteinuria in 2 siblings with FLD, and was decreased on fat restriction in another patient with FLD ( Figure 2) . Indeed, abnormal lipoproteins with size of ≈100 nm corresponding to Lp1 have been identified in patients with LCAT deficiency with renal failure. 2, 11, 12, 15 The lipid composition of Lp1 did not change on incubation with rLCAT (data not shown). Together, this suggests that Lp1 is most likely secondary to renal failure rather than directly caused by LCAT deficiency.
As opposed to controls, Fr. 8 was richer in total cholesterol, TG, FC, and PL than Fr. 9 in the patients with LCAT deficiency (Figures 1 and 4B ). Lp8 also differed in composition between FLD and FED: in FLD, it contained increased TG and decreased CE in comparison with FED ( Figure 3A) . Importantly, although the levels varied with the severity of renal damage as did those in Lp1, the buoyance of the peak at Fr. 8 did not vary with severity of renal damage (Figure 2) , strongly suggesting that Lp8 directly results from a lack of LCAT and not from metabolic disturbances that occur during proteinuria and progressive renal failure.
In addition to the above-mentioned characteristics for Lp8 in LCAT-deficiency syndrome, HPLC-GFC analyses clarified novel unique lipid properties of Lp8 in FLD in comparison with that in FED; the averaged sizes of Lp8 are smaller in FLD than those in FED ( Figure 3C ). The lipid compositions of Lp8 in FLD were, in part, ameliorated by rLCAT incubation ( Figure 4A ). The averaged sizes of the Lp8 increased in FLD, whereas those in FED decreased ( Figure 4C ). rLCAT increased the CE formation in both LDL and HDL fractions in FLD sera. Thus, these findings indicated that the abnormal compositions were most likely caused primarily by the dysfunction of LCAT in the patients, and that the abnormal characteristics of Lp8 were not because of metabolic disturbances that occur during proteinuria and progressive loss of kidney function.
Previous extensive analyses using electron microscopy have identified 3 abnormal lipoproteins in the LDL fraction of FLD 12 : TG-rich and CE-poor particles of sizes similar to normal LDL (FLD-LDL); FC-and PL-containing particles of sizes distributing from 40 to 60 nm (LpX-like particle) 2 ; particles with a diameter of 100 nm (designated as LM-LDL) 17, 30 that were later reported to be identical to LpX. 15 LpX is FCand PL-rich but TG-poor lipid particles (30%, 60%, and 2%, respectively) 22 without apolipoproteins, which range from very low density lipoprotein to large LDL fractions in fast performance liquid chromatography analysis. 31 The abnormal particles have been shown to be decreased by lipid-lowering therapy in a patient with FLD. 21 Lipoproteins in Lp8 were different from LpX in the lipid contents; the fractions were rich in FC and PL and also rich in TG (13.2±1.3%, 41.4±3.3%, and 45.8±3.8%, respectively). The composition analyses suggested that Lp8 corresponds to FLD-LDL, but the calculated sizes of Lp8 were larger than normal LDL using the data obtained by size fractionation with HPLC-GPC in the present study. Thus, the identified Lp8 in LCAT-deficiency syndrome was most likely not identical to LpX in the characteristics.
There is a limitation for the interpretation of the quantitative measurement of LpX in the frozen samples collected in our study because the abnormal lipoproteins were known to be labile to freezing-and-thawing treatment. In this context, fresh sera were collected from patients 2 and 4 and analyzed by agarose gel electrophoresis. The lipid staining of lipoproteins electrophoresed in agarose gel detected the abnormally slowly migrating TG-poor lipoproteins, LpX, at the expectedly migrating position, as well as TG-rich abnormal β-lipoproteins (LDL) in the once-frozen sample, as well as the fresh sample in patient 4, although the staining intensity tended to decrease in comparison with the fresh counterpart. However, LpX was not detected in either sample with or without freeze-andthaw treatment from patient 2. Thus, LpX was indeed labile to freeze/thawing, and the frozen samples were not adequate for the quantitative measurement. However, the presence was still able to be evaluated after once-freezing treatment. On the basis of background data, HPLC-GFC analysis showed that lipid contents in Lp8 were not largely affected by once-freezing treatment in both patients 2 and 4: in contrast, the contents of TG and PL were slightly decreased in lipoproteins with peak of Fr. 5 (data not shown). Additional studies using fresh samples of patients with distinct mutations and manifestations are needed to interpret the significance of novel lipoproteins in comparison with LpX for the development of renal insufficiency in LCAT0deficiency syndrome quantitatively.
In FLD but not in FED, Lp12 to 16 were heterogeneous in size and rich in PL. rLCAT decreased PL in these fractions specifically ( Figure 5D ; Figure II in the online-only Data Supplement). This may suggest that the heterogeneous-sized PL-rich particles in Fr. 12 to 16 converge to normal-sized HDL (Fr. 16-18) on incubation with rLCAT, with concomitant esterification of FC.
In conclusion, 4 lipoprotein fractions specific to LCATdeficiency syndromes were identified by the HPLC-GFC analysis of samples from genetically diagnosed patients with different mutations and manifestations. The composition of 2 of these was unique to only FLD; these were not likely compatible with the previously reported LpX. These abnormal lipoproteins may be causal to the renal pathology in FLD, the main cause of increased morbidity and mortality in this condition. The regular evaluation of these specific lipid fractions during LCAT enzyme replacement therapy in patients with LCAT deficiency may provide guidance for success of the intervention. The value of these lipid fractions for risk of future renal disease needs to be addressed in prospective follow-up studies in patients with FLD with various mutations in the LCAT gene before the onset of proteinuria.
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